Cogent Biosciences, Inc.

NASDAQ
COGT
Stock
Yield per half year: -49.92%
Dividend yield: 0%
Sector: Healthcare

Share chart Cogent Biosciences, Inc.

Extended chart Simple chart
Financial Markets by TradingView

About Cogent Biosciences, Inc.

Биофармацевтическая компания Unum Therapeutics Inc. специализируется на разработке ряда новых методов лечения онкологических больных. Новая запатентованная технология компании, известная как Bolt-On Chimeric Receptor (BOXR), разработана для улучшения функциональности сконструированных Т-клеток путем обнаружения и включения трансгена «болт-на» в сконструированные Т-клетки пациента для преодоления резистентности микроокружение солидной опухоли для атаки Т-клеток.

more details
Его расширенная программа, PLX9486, представляет собой селективный ингибитор KIT D816V, который разрабатывается для лечения пациентов с системным мастоцитозом и опухолями стромы желудочно-кишечного тракта. Компания была основана в 2014 году, ее штаб-квартира находится в Кембридже, штат Массачусетс.
Add to compare list
Add to watchlist
Add to portfolio
Add to notification price

Main settings

IPO date 2018-03-29
ISIN US19240Q2012
Industry Biotechnology
Sector Health Care
Валюта usd
Валюта отчета usd
Сайт link
Цена ао 4.82
Change price per day: 0% (4.82)
Change price per week: -3.21% (4.98)
Change price per month: +6.87% (4.51)
Change price per 3 month: -35.39% (7.46)
Change price per half year: -49.92% (9.625)
Change price per year: -41.36% (8.22)
Change price per 3 year: +11.32% (4.33)
Change price per 5 year: +864.39% (0.4998)
Change price per year to date: -37.89% (7.76)
All parameters

Grade

Underestimation
Title Value Grade
P/S 861.15 1
P/BV 3.12 5
P/E 0 0
EV/EBITDA -2.61 0
Total: 3.38
Efficiency
Title Value Grade
ROA, % -79.79 0
ROE, % -99.54 0
Total: 0
Dividends
Title Value Grade
Div yield, % 0 0
DSI 0 0
Total: 0
Debt
Title Value Grade
Debt/EBITDA -0.0633 10
Total: 10
Growth impulse
Title Value Grade
Yield Revenue, % -96.1 0
Yield Ebitda, % 207.65 10
Yield EPS, % -84.76 0
Total: 6
More

Main owners

Institutions Volume Share, %
Blackrock Inc. 6 755 584 7.07
Kynam Capital Management, LP 5 854 766 6.12
Tcg Crossover Management, Llc 5 631 042 5.89
COMMODORE CAPITAL LP 5 566 026 5.82
FMR, LLC 5 302 854 5.55
Point72 Asset Management, L.P. 5 191 448 5.43
VR Adviser, LLC 4 684 167 4.9
Vanguard Group Inc 4 534 655 4.74
State Street Corporation 4 150 615 4.34
Suvretta Capital Management, LLC 3 710 539 3.88

Contained in ETF

ETFShare, %Profitability for 1 year, %Dividends, %
Future Tech ETF 0.1166 426.34 0.8416
Principal Healthcare Innovators ETF 0.1166 618.5 0.8416
iShares Morningstar Small-Cap Growth ETF 0.02305 595.05 0.72598
iShares Morningstar Small-Cap ETF 0.01798 391.25 1.60498
iShares Morningstar Small-Cap Value ETF 0.01318 187.77 2.50476
0.06443.781.3

Similar companies

P/E & P/BVEV/Ebitda & Debt/Ebitda


Company management

Head Job title Payment Year of birth
Mr. Andrew R. Robbins M.B.A. President, CEO & Director 1.06M 1976 (49 years)
Mr. John L. Green C.A., CPA CFO & Principal Accounting Officer 763.99k 1980 (45 years)
Dr. Jessica Sachs M.D. Chief Medical Officer 773.92k 1975 (50 years)
Mr. Brad Barnett Chief Technology Officer N/A
Dr. John Edward Robinson Ph.D. Chief Scientific Officer 749.89k 1975 (50 years)
Ms. Erin Schellhammer Chief People Officer N/A
Mr. Evan D. Kearns J.D. Chief Legal Officer & Corporate Secretary N/A 1980 (45 years)
Mr. Dana R. Martin Pharm.D. Senior VP of Medical Affairs & Chief Patient Officer N/A
Brad Fell Senior Vice President of Chemistry N/A
Ms. Christi Waarich Senior Director of Investor Relations

About company

Address: United States, Cambridge, 200 Cambridge Park Drive - Open in google maps, Open in yandex maps
Website: http://www.cogentbio.com